Ravulizumab
Evidence-based neurology checklist on ravulizumab: Pharmacology It is indicated for AchR antibody positive myasthenia gravis It is usually indicated in refractory cases This is usually in patients resistant to Eculizumab Dosing Administration Frequent adverse events Precautions Benefits Non-MG…
Pharmacology
- It is indicated for AchR antibody positive myasthenia gravis
- It is usually indicated in refractory cases
- This is usually in patients resistant to Eculizumab
Dosing
Administration
Frequent adverse events
Precautions
Benefits
Non-MG indications
References
- Nair SS, Jacob S. Novel immunotherapies for myasthenia gravis. Immunotargets Ther 2023; 12:25-45.
- Sánchez-Tejerina D, Sotoca J, Llaurado A, López-Diego V, Juntas-Morales R, Salvado M. New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med 2022; 11:6394.Vanoli F, Mantegazza R. Ravulizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther 2023; 23:235-241.
- Meisel A, Annane D, Vu T, Mantegazza R, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 2023; 270:3862-3875.
